Enhanc3D Genomics, an innovator in 3D genomics technology, has launched a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.

Based on the Company’s proprietary 3D genomics platform, integrated with extensive multi-omics analysis, the new 3D Multi-omic offerings provide partners with an end-to-end solution to support and enhance decision-making through every stage of the drug discovery and development process.

Enhanced’s 3D Multi-omic platform is based on patented Promoter Capture Hi-C technology, offering high-resolution, genome-wide regulatory maps of any cell type, sub-type, or state, by capturing interactions between promoters and regulatory regions. The platform is uniquely able to analyze these interactions across the entire genome within one assay. By integrating 3D genomic data and data from the 3D Multi-Omic Atlas, the Company’s extensive repository of multi-omic data across human cell types, the new solutions provide deep, data-driven insights into disease mechanisms and therapeutic opportunities.

The new suite of multi-omics solutions offers differentiated capabilities across the entire drug development pipeline to support partners through their drug discovery journey.

“By harnessing the full potential of the non-coding genome our unique technology not only has the potential to accelerate the target discovery process, but can also be used to unveil new therapeutic possibilities,” said Dr. Hazel Jones, CEO of Enhanc3D Genomics. “We have shown, through existing collaborations, that we can improve both timescales and success rates of target identification and drug development using 3D multi-omics.”

Dr. Dan Turner, CSO, Enhanc3D Genomics, added: “Created using data generated from our 3D genomics platform together with other multi-omic datasets, our 3D Multi-Omic Atlas provides the foundation for deep cell-specific insights into gene regulation and disease mechanisms. Offering partners access to our 3D genomics platform and 3D Multi-Omic Atlas through our new suite of integrated solutions, alongside our visualization software, enables us to support innovators driving precision medicine approaches, to transform drug discovery and development.”